Delta 8 THC Chewable Mints 5 mg Double Mint by FluxxLab

INSUFFICIENT RELIABLE EVIDENCE to RATE

• Chemotherapy-induced nausea and vomiting (CINV). Although there is interest in using oral delta-8-THC for CINV, there is insufficient reliable information about the clinical effects of delta-8-THC for this purpose.
• Glaucoma. Although there is interest in using oral delta-8-THC for glaucoma, there is insufficient reliable information about the clinical effects of delta-8-THC for this condition.
• Insomnia. Although there is interest in using oral delta-8-THC for insomnia, there is insufficient reliable information about the clinical effects of delta-8-THC for this condition. More evidence is needed to rate delta-8-THC for these uses.

(Read more about DELTA-8-TETRAHYDROCANNABINOL (DELTA-8-THC))

LIKELY EFFECTIVE

• Cystic fibrosis. Long-term nebulized hypertonic sodium chloride improves lung function and reduces pulmonary exacerbations in patients with cystic fibrosis. Details: Meta-analyses of clinical research in adults with cystic fibrosis show that, when taken along with a bronchodilator and other standard therapies, nebulized hypertonic sodium chloride in concentrations of 3% to 7%, up to 10 mL twice daily for 4 weeks, increases forced expiratory volume at one second (FEV1) when compared with isotonic saline (sodium chloride 0.9%) (26230,26230). This benefit was not seen at 48 weeks. Other clinical research in adults with cystic fibrosis shows that inhaling sodium chloride 7%, 4 mL twice daily for 48 weeks, does not improve FEV1 when compared with isotonic saline. However, chronic treatment with hypertonic saline does reduce the number of pulmonary exacerbations and increase the number of patients without pulmonary exacerbations when compared with isotonic saline (29402). It is not clear if this benefit occurs in children with cystic fibrosis. The Pulmonary Clinical Practice Guidelines Committee of the Cystic Fibrosis Foundation recommends that individuals with cystic fibrosis aged 6 years or older use nebulized hypertonic saline long-term to improve lung function, reduce the number of exacerbations, and improve quality of life (29403).

POSSIBLY EFFECTIVE

• Amphotericin B nephrotoxicity. Oral sodium chloride seems to prevent nephrotoxicity associated with use of amphotericin B. Details: Clinical research shows that administering oral or intravenous sodium chloride 150 mEq daily during treatment with amphotericin B can attenuate the rise in serum creatinine levels and preserve renal function when compared to treatment with amphotericin B alone (26226).

INSUFFICIENT RELIABLE EVIDENCE to RATE

• Bipolar disorder. It is unclear if oral sodium is beneficial in preventing lithium level fluctuations in patients with bipolar disorder. Details: A moderate-sized open-label clinical study in adults with type I bipolar disorder receiving lithium carbonate shows that taking sodium chloride 1 gram daily for 12 weeks along with dietary salt restriction of 1 gram daily reduces the percentage of patients with lithium level fluctuations above 0.8 mEq/L, but does not significantly affect serum sodium, potassium, aldosterone, or creatinine levels when compared with controls who were not salt restricted, but were advised not to consume additional salt at the table (112909). However, the interpretation of these findings is limited by missing data in both groups.
• Canker sores. Although there is interest in using topical sodium chloride for canker sores, there is insufficient reliable information about the clinical effects of sodium chloride for this condition.
• Congestive heart failure. It is unclear if oral sodium is beneficial in patients with acute decompensated heart failure requiring decongestive therapy with diuretics. Details: A moderate-sized clinical study in adults hospitalized with acute decompensated heart failure requiring high-dose intravenous furosemide shows that taking sodium chloride 2 grams three times daily for up to 96 hours does not affect patient weight or serum creatinine levels when compared with placebo (112911). However, the clinical relevance of this study is unclear and it may have been inadequately powered to detect a difference between groups.
• Conjunctivitis. Although there is interest in using ophthalmic sodium chloride for conjunctivitis, there is insufficient reliable information about the clinical effects of sodium chloride for this condition.
• Hyponatremia. Although there is interest in using oral sodium chloride for hyponatremia, there is insufficient reliable information about the clinical effects of oral sodium chloride for this condition.
• Pharyngitis. Although there is interest in using topical sodium chloride for pharyngitis, there is insufficient reliable information about the clinical effects of sodium chloride for this condition.
• Prematurity. It is unclear if oral sodium is beneficial for premature infants. Details: Preliminary clinical research in infants born at less than 32 weeks' gestation shows that adding sodium 4 mEq/kg daily to enteral feedings, starting from the 7th day after birth and continuing through the 35th day, reduces the risk of developing hyponatremia and improves weight gain when compared with adding water (98180). A small, open-label clinical study in newborns less than 35 weeks gestation shows that high sodium intake, defined as an average of 0.25% sodium in maintenance fluids, for 48 hours on day 2 and 3 after birth results in less weight loss within the first 72 hours of life when compared with control, but does not improve mortality, length of hospital stay, or complications from prematurity (112908). However, interpretation of these findings is limited by varied concentrations of sodium as an intervention. More evidence is needed to rate sodium for these uses.

(Read more about SODIUM)

There is insufficient reliable information available about the safety of delta-8-THC.

CHILDREN: POSSIBLY UNSAFE
when used orally. Delta-8-THC-containing gummies and other products resembling candy or cookies have been mistakenly consumed by children, resulting in hospital admission (106107,106108,107322,113033). Deep sedation with low blood pressure and a slowed heart rate have occurred (106108,107322).

PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.

(Read more about DELTA-8-TETRAHYDROCANNABINOL (DELTA-8-THC))

LIKELY SAFE ...when used orally and appropriately. Sodium is safe in amounts that do not exceed the Chronic Disease Risk Reduction (CDRR) intake level of 2.3 grams daily (100310). Higher doses can be safely used therapeutically with appropriate medical monitoring (26226,26227).

POSSIBLY UNSAFE ...when used orally in high doses. Tell patients to avoid exceeding the CDRR intake level of 2.3 grams daily (100310). Higher intake can cause hypertension and increase the risk of cardiovascular disease (26229,98176,98177,98178,98181,98183,98184,100310,109395,109396,109398,109399). There is insufficient reliable information available about the safety of sodium when used topically.

CHILDREN: LIKELY SAFE
when used orally and appropriately (26229,100310). Sodium is safe in amounts that do not exceed the CDRR intake level of 1.2 grams daily for children 1 to 3 years, 1.5 grams daily for children 4 to 8 years, 1.8 grams daily for children 9 to 13 years, and 2.3 grams daily for adolescents (100310).

CHILDREN: POSSIBLY UNSAFE
when used orally in high doses. Tell patients to avoid prolonged use of doses exceeding the CDRR intake level of 1.2 grams daily for children 1 to 3 years, 1.5 grams daily for children 4 to 8 years, 1.8 grams daily for children 9 to 13 years, and 2.3 grams daily for adolescents (100310). Higher intake can cause hypertension (26229).

PREGNANCY AND LACTATION: LIKELY SAFE
when used orally and appropriately. Sodium is safe in amounts that do not exceed the CDRR intake level of 2.3 grams daily (100310).

PREGNANCY AND LACTATION: POSSIBLY UNSAFE
when used orally in higher doses. Higher intake can cause hypertension (100310). Also, both the highest and the lowest pre-pregnancy sodium quintile intakes are associated with an increased risk of hypertensive disorders of pregnancy, including gestational hypertension and pre-eclampsia, and the delivery of small for gestational age (SGA) infants when compared to the middle intake quintile (106264).

(Read more about SODIUM)

(Read more about DELTA-8-TETRAHYDROCANNABINOL (DELTA-8-THC))

ANTIHYPERTENSIVE DRUGS Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Probable •  Level of Evidence = A Theoretically, a high intake of dietary sodium might reduce the effectiveness of antihypertensive drugs.  Details High intake of dietary sodium can increase systolic and diastolic blood pressure (26222). Also, high intake of sodium may necessitate increased use of antihypertensive medications to achieve blood pressure control in some patients, such as those with chronic kidney disease (26223).

CORTICOSTEROIDS Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Concomitant use of mineralocorticoids and some glucocorticoids with sodium supplements might increase the risk of hypernatremia.  Details Mineralocorticoids and some glucocorticoids (corticosteroids) cause sodium retention. This effect is dose-related and depends on mineralocorticoid potency. It is most common with hydrocortisone, cortisone, and fludrocortisone, followed by prednisone and prednisolone (4425).

LITHIUM Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Probable •  Level of Evidence = B Altering dietary intake of sodium might alter the levels and clinical effects of lithium.  Details High sodium intake can reduce plasma concentrations of lithium by increasing lithium excretion (26225). Reducing sodium intake can significantly increase plasma concentrations of lithium and cause lithium toxicity in patients being treated with lithium carbonate (26224,26225). Stabilizing sodium intake is shown to reduce the percentage of patients with lithium level fluctuations above 0.8 mEq/L (112909). Patients taking lithium should avoid significant alterations in their dietary intake of sodium.

SODIUM-CONTAINING DRUGS Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Concomitant use of sodium-containing drugs with additional sodium from dietary or supplemental sources may increase the risk of hypernatremia and long-term sodium-related complications.  Details The Chronic Disease Risk Reduction (CDRR) intake level of 2.3 grams of sodium daily indicates the intake at which it is believed that chronic disease risk increases for the apparently healthy population (100310). Some medications contain high quantities of sodium. When used in conjunction with sodium supplements or high-sodium diets, the CDRR may be exceeded. Additionally, concomitant use may increase the risk for hypernatremia; this risk is highest in the elderly and people with other risk factors for electrolyte disturbances.

TOLVAPTAN (Samsca) Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Probable •  Level of Evidence = C Theoretically, concomitant use of tolvaptan with sodium might increase the risk of hypernatremia.  Details Tolvaptan is a vasopressin receptor 2 antagonist that is used to increase sodium levels in patients with hyponatremia (29406). Patients taking tolvaptan should use caution with the use of sodium salts such as sodium chloride.

(Read more about SODIUM)

General ...There is limited information available about the safety of delta-8-THC. A thorough evaluation of safety outcomes has not been conducted.
Most Common Adverse Effects:
Orally: Anxiety, cough, difficulty thinking and speaking, dream-like state, euphoria, feeling "high", paranoia, and vision and time distortion.
Serious Adverse Effects (Rare):
Orally: Brugada EKG pattern, cannabinoid hyperemesis syndrome (CHS).

Cardiovascular ...An otherwise healthy 31-year-old male experienced sudden onset substernal, non-exertional chest pain within 20 minutes of taking a gummy containing delta-8-THC. Brugada type I pattern was noted on EKG, with notable progression from a baseline EKG 2 months prior that showed Brugada type III pattern. EKG returned to baseline by 16 hours post-ingestion and the Brugada pattern ultimately resolved by one-month follow up (107323). Three cases report tachycardia in pediatric patients after unintentional ingestion of delta-8-THC that resolved with supportive care (113033,113042).

Gastrointestinal ...A 38-year-old female developed cannabinoid hyperemesis syndrome (CHS) after taking gummies containing delta-8-THC most nights of the week for approximately one month. Symptoms resolved almost immediately after treatment with topical capsaicin cream and intravenous haloperidol 5 mg (106104). A case in a 6-year-old female reports nausea and vomiting after ingestion of delta-8-THC gummies that resolved over 2 days with supportive care (113042).

Neurologic/CNS ...Delta-8-THC has been reported to cause psychoactive effects and a feeling of being "high". It is estimated to be 50% to 75% as psychoactive as delta-9-THC, the primary psychoactive constituent of cannabis. Effects include euphoria, vision and time distortion, difficulty thinking and speaking, and a dream-like feeling (106100,106107,106108). A large case series reports neurologic disorders (e.g., dizziness, somnolence, altered consciousness) as some of the most frequently noted adverse effects with delta-8-THC after assessing a public forum of 98,700 subscribers (113017). Of 183 adverse events related to delta-8-THC reported to the US Food and Drug Administration, 16 report occurrence of seizure (113026). A 2-year-old child presented with sedation and acute encephalopathy requiring intubation following accidental ingestion of gummies containing an estimated delta-8-THC dose of 15 mg/kg. Resolution occurred after approximately 1.5 days of supportive care (107322). Six cases in pediatric patients, ranging from 18 months old to 16 years old, report 5 ingestions and 1 inhalation of delta-8-THC resulting in neurologic presentations (e.g., lethargy, somnolence, agitation, dizziness, unresponsiveness, or possible seizure) requiring supportive care. Resolution occurred over 2 days in most cases (113033,113042).

Psychiatric ...A large case series reports psychiatric disorders as some of the most frequently noted adverse effects with delta-8-THC after assessing a public forum of 98,700 subscribers. Furthermore, anxiety and paranoia were 2 of the most cited adverse effect terms, about 16% and 9%, respectively (113017). Additionally, 3 cases report psychosis in adults after ingesting or inhaling delta-8-THC. All 3 patients required admission to a psychiatric hospital and antipsychotic medications prior to discharge. However, 2 of the patients had underlying psychiatric histories (113047).

Pulmonary/Respiratory ...A large case series reports pulmonary disorders g., cough, dry throat, dyspnea, painful respiration) as some of the most frequently noted adverse effects with delta-8-THC after assessing a public forum of 98,700 subscribers (113017). Of 183 adverse events related to delta-8-THC reported to the US Food and Drug Administration, 33 report dyspnea, 17 report respiratory disorder, and 15 report cough (113026). Additionally, 2 cases in pediatric patients report slowed respiratory breathing with varying initial presentations of somnolence and agitation after ingesting delta-8-THC in the form of candy at doses of 16 mg/kg and 38 mg/kg. Resolution occurred in both cases with supportive care and intensive care admission for approximately 2 days (113033).

Other ...Based on statistics from the American Association of Poison Control Centers, hospitalization occurred in 18% of 661 reported exposures to delta-8-THC in the first 7 months of 2021 (106108). In the 8-month period ending in July 2021, 14 of 22 cases reported to the US FDA presented to the hospital for adverse effects related to delta-8-THC-containing products (106107). In addition, the CDC's National Syndromic Surveillance Program (NSSP) has found an increase in visits to emergency departments due to complaints related to delta-8-THC (106108). Symptoms of delta-8-THC intoxication include vomiting, lethargy, hallucinations, lack of muscle coordination, increased and decreased heart rate, low blood pressure, difficulty breathing, and coma (106107,106108,107322).

(Read more about DELTA-8-TETRAHYDROCANNABINOL (DELTA-8-THC))

General ...Orally, sodium is well tolerated when used in moderation at intakes up to the Chronic Disease Risk Reduction (CDRR) intake level. Topically, a thorough evaluation of safety outcomes has not been conducted.
Serious Adverse Effects (Rare):
Orally: Worsened cardiovascular disease, hypertension, kidney disease.

Cardiovascular ...Orally, intake of sodium above the CDRR intake level can exacerbate hypertension and hypertension-related cardiovascular disease (CVD) (26229,98176,100310,106263). A meta-analysis of observational research has found a linear association between increased sodium intake and increased hypertension risk (109398). Observational research has also found an association between increased sodium salt intake and increased risk of CVD, mortality, and cardiovascular mortality (98177,98178,98181,98183,98184,109395,109396,109399). However, the existing research is unable to confirm a causal relationship between sodium intake and increased cardiovascular morbidity and mortality; high-quality, prospective research is needed to clarify this relationship (100312). As there is no known benefit with increased salt intake that would outweigh the potential increased risk of CVD, advise patients to limit salt intake to no more than the CDRR intake level (100310).
A reduction in sodium intake can lower systolic blood pressure by a small amount in most individuals, and diastolic blood pressure in patients with hypertension (100310,100311,106261). However, post hoc analysis of a small crossover clinical study in White patients suggests that 24-hour blood pressure variability is not affected by high-salt intake compared with low-salt intake (112910). Additionally, the available research is insufficient to confirm that a further reduction in sodium intake below the CDRR intake level will lower the risk for chronic disease (100310,100311). A meta-analysis of clinical research shows that reducing sodium intake increases levels of total cholesterol and triglycerides, but not low-density lipoprotein (LDL) cholesterol, by a small amount (106261).
It is unclear whether there are safety concerns when sodium is consumed in amounts lower than the adequate intake (AI) levels. Some observational research has found that the lowest levels of sodium intake might be associated with increased risk of death and cardiovascular events (98181,98183). However, this finding has been criticized because some of the studies used inaccurate measures of sodium intake, such as the Kawasaki formula (98177,98178,101259). Some observational research has found that sodium intake based on a single 24-hour urinary measurement is inversely correlated with all-cause mortality (106260). The National Academies Consensus Study Report states that there is insufficient evidence from observational studies to conclude that there are harmful effects from low sodium intake (100310).

Endocrine ...Orally, a meta-analysis of observational research has found that higher sodium intake is associated with an average increase in body mass index (BMI) of 1. 24 kg/m2 and an approximate 5 cm increase in waist circumference (98182). It has been hypothesized that the increase in BMI is related to an increased thirst, resulting in an increased intake of sugary beverages and/or consumption of foods that are high in salt and also high in fat and energy (98182). One large observational study has found that the highest sodium intake is not associated with overweight or obesity when compared to the lowest intake in adolescents aged 12-19 years when intake of energy and sugar-sweetened beverages are considered (106265). However, in children aged 6-11 years, usual sodium intake is positively associated with increased weight and central obesity independently of the intake of energy and/or sugar-sweetened beverages (106265).

Gastrointestinal ...In one case report, severe gastritis and a deep antral ulcer occurred in a patient who consumed 16 grams of sodium chloride in one sitting (25759). Chronic use of high to moderately high amounts of sodium chloride has been associated with an increased risk of gastric cancer (29405).

Musculoskeletal ...Observational research has found that low sodium levels can increase the risk for osteoporosis. One study has found that low plasma sodium levels are associated with an increased risk for osteoporosis. Low levels, which are typically caused by certain disease states or chronic medications, are associated with a more than 2-fold increased odds for osteoporosis and bone fractures (101260).
Conversely, in healthy males on forced bed rest, a high intake of sodium chloride (7.7 mEq/kg daily) seems to exacerbate disuse-induced bone and muscle loss (25760,25761).

Oncologic ...Population research has found that high or moderately high intake of sodium chloride is associated with an increased risk of gastric cancer when compared with low sodium chloride intake (29405). Other population research in patients with gastric cancer has found that a high intake of sodium is associated with an approximate 65% increased risk of gastric cancer mortality when compared with a low intake. When zinc intake is taken into consideration, the increased risk of mortality only occurred in those with low zinc intake, but the risk was increased to approximately 2-fold in this sub-population (109400).

Pulmonary/Respiratory ...In patients with hypertension, population research has found that sodium excretion is modestly and positively associated with having moderate or severe obstructive sleep apnea. This association was not found in normotensive patients (106262).

Renal ...Increased sodium intake has been associated with impaired kidney function in healthy adults. This effect seems to be independent of blood pressure. Observational research has found that a high salt intake over approximately 5 years is associated with a 29% increased risk of developing impaired kidney function when compared with a lower salt intake. In this study, high salt intake was about 2-fold higher than low salt intake (101261).

(Read more about SODIUM)